Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Ascletis Received IND Approval for its NASH Drug 2019-08-28 08:00
Ascletis Opens Clinical Development Shanghai Center 2019-08-12 18:00
Ascletis Received IND Approval and Management Outlook of 2019 and Beyond 2019-08-05 08:00
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH 2019-05-01 06:00
Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease 2019-04-15 17:12
Ascletis Appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China 2019-03-01 08:00
Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing 2019-02-13 08:00
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases 2019-01-14 08:30
Ascletis' IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA 2019-01-03 08:00
Ascletis' Ganovo Enrolled in the Basic Medical Insurance of Chengdu 2019-01-02 08:00
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis 2018-11-20 18:30
Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer 2018-11-12 07:30
Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD 2018-11-06 08:00
Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA 2018-10-18 16:30
Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients 2018-10-15 16:30
Ganovo Enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program 2018-09-26 06:30
Ascletis Appoints Mr. Joshua Zhongbao Ling as VP Finance 2018-08-30 16:40
1 4 5 6 7 8